Nociceptive Neurons
Suppression of hyperexcitability of trigeminal nociceptive neurons associated with inflammatory hyperalgesia following systemic administration of lutein via inhibition of cyclooxygenase-2 cascade signaling
10
SDF1–CXCR4 signaling contributes to persistent pain and hypersensitivity via regulating excitability of primary nociceptive neurons: involvement of ERK-dependent Nav1.8 up-regulation
14
Nociceptive neurons detect cytokines in arthritis
9
Runx transcription factors in neuronal development
7
Comparison of the transport of QX-314 through TRPA1, TRPM8, and TRPV1 channels
8
THE ROLE OF THE THALAMUS IN MODULATING PAIN
8
The G Protein regulators EGL-10 and EAT-16, the Giα GOA-1 and the Gqα EGL-30 modulate the response of the C. elegansASH polymodal nociceptive sensory neurons to repellents
13
The acute nociceptive signals induced by bradykinin in rat sensory neurons are mediated by inhibition of M type K+ channels and activation of Ca2+ activated Cl– channels
14
Interleukin 6 dependent influence of nociceptive sensory neurons on antigen induced arthritis
13
Fine grained nociceptive maps in primary somatosensory cortex
22
Decanoic acid attenuates the excitability of nociceptive trigeminal primary and secondary neurons associated with hypoalgesia
10
Intense isolectin B4 binding in rat dorsal root ganglion neurons distinguishes c fiber nociceptors with broad action potentials and high nav1 9 expression
13
Characterization of ectonucleotidases in nociceptive circuits
369
Influences of smoking and caffeine consumption on trigeminal pain processing
6
The effect of nerve injury on the spinal and peripheral actions of galanin and interleukin-6 on sensory processing
248
M‐type K⁺ channels in peripheral nociceptive pathways
15
Square Neurons, Power Neurons, and Their Learning Algorithms
18
Central effects of acetylsalicylic acid on trigeminal-nociceptive stimuli
6
INVESTIGATION OF ANALGESIC ACTIVITY OF AMARANTHUS SPINOSUS LINN. (LEAVES) FROM BANGLADESH IN SWISS ALBINO MICE
6
Integrating osteopathic approaches based on biopsychosocial therapeutic mechanisms. Part 2: Clinical approach
30